Last reviewed · How we verify
CTX-4430
CTX-4430 is a small molecule inhibitor of the NADPH oxidase 2 (NOX2) enzyme.
CTX-4430 is a small molecule inhibitor of the NADPH oxidase 2 (NOX2) enzyme. Used for Chronic Granulomatous Disease.
At a glance
| Generic name | CTX-4430 |
|---|---|
| Sponsor | Celtaxsys, Inc. |
| Drug class | NADPH oxidase 2 inhibitor |
| Target | NOX2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
NOX2 is a key component of the respiratory burst in phagocytes, and its inhibition has been shown to reduce inflammation and oxidative stress. CTX-4430 works by selectively inhibiting the activity of NOX2, which may help to mitigate the symptoms of certain inflammatory diseases.
Approved indications
- Chronic Granulomatous Disease
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Trial of Acebilustat for the Treatment of Upper Arm Lymphedema (PHASE2)
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol (PHASE2)
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol (PHASE2)
- EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients (PHASE2)
- Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430) (PHASE1)
- CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris (PHASE2)
- Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients (PHASE1)
- Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CTX-4430 CI brief — competitive landscape report
- CTX-4430 updates RSS · CI watch RSS
- Celtaxsys, Inc. portfolio CI